Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
9989.HK News Today: Stay Updated with the Latest Shenzhen Hepalink Pharmaceutical Group Co., Ltd. News in Real Time
Find 9989.HK news now at Meyka AI. Stay informed with the latest Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stocks updates, including price news, market analysis, and expert insights.
European Stocks Advance with Earnings in Focus; Adidas Jumps on Strong Performance
European Stocks moved higher as investors closely watched fresh corporate earnings and company guidance across major sectors. Strong business updates from leading companies helped improve market sentiment, while sportswear giant Adidas stood out with a sharp rise after reporting better-than-expected performance. The positive movement in the stock market reflected growing investor confidence, especially as companies…
Seven-Eleven Bread Sale April 29: 100 Yen Deals Return
Seven-Eleven’s bread sale offers six items at 100 yen during morning hours as part of the 52nd anniversary “Gratitude Festival” promotion.
TCS.NS Stock Gains 1.12% on 29 Apr 2026 – NSE Intraday Analysis
TCS.NS stock rises 1.12% to INR 2,475 on NSE today. Market cap at INR 8.85T with strong fundamentals and B+ grade rating.
ECAT: Saba Capital Sells 44K Shares on April 29, 2026
Saba Capital Management sold 44,101 ECAT shares at $14.79 on April 27, 2026. 10% owner reduces position in BlackRock ESG Capital Allocation Trust.
ORKA Maintained at Buy by UBS with $100 Price Target, April 2026
UBS maintained ORKA at Buy rating with $100 price target raised from $75 on April 28, 2026.
Gold Price Holds Near $4,590 After Slide as Iran War Fuels Inflation and Rate Uncertainty
The global Gold Price is holding steady near the $4,590 per ounce level after recent volatility in the market. The yellow metal has faced a sharp rise and correction phase, but it continues to attract attention from investors worldwide. We are seeing a complex mix of factors driving this movement. The ongoing Iran conflict, rising…
PKG Neutral Rating Maintained by UBS on April 29, 2026
UBS maintained Neutral rating on PKG, raising price target to $232 from $225. Stock trades at $222.59 with B+ grade.
OSE.PA stock surges 16% on FDA orphan drug designation for VEL-101
OSE.PA jumps 16.18% to €4.25 on FDA orphan drug designation for partner Veloxis’ VEL-101 heart transplant therapy.
SNDK Earnings Preview: Sandisk Reports April 30 Results
Sandisk (SNDK) earnings preview for April 30, 2026. EPS estimate $14.43, revenue $4.69B. Analyst consensus bullish with 29 buy ratings.